Nutra Pharma Announces First Manufacturing Release of Nyloxin Rx, a Prescription Treatment for Chronic Pain
Nutra Pharma (OTCBB:NPHC) has announced that it has completed the first production run of its prescription pain drug, Nyloxin Rx, and has successfully released it for initial marketing-related distribution
"We are pleased to be announcing the rollout of the Company's first prescription drug, Nyloxin Rx," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As we move forward with the launch of Nyloxin Rx, we continue to seek partnerships with established U.S. and international distributors to assist us with ongoing marketing to physician offices, hospitals and medical clinics," he added.
Nyloxin Rx is a prescription pain reliever clinically proven to treat Stage 3 (severe) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one's ability to fully function.
The drug, which was developed by Nutra Pharma's whollyowned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating angina pectoris, angina faucium, back pain, headaches, joint pain, migraines, neck pain, neuralgia, ovarian pain, and painful periods and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Currently, physicians can request samples of Nyloxin Rx by visiting the Healthcare Providers section of the Nyloxin website: http://www.Nyloxin.com/healthcare_providers.
About Nutra Pharma Corp.
Nutra Pharma Corporation (OTCBB:NPHC) (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's whollyowned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's whollyowned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.